Palimpsest Bio Corp. raises $1M in first Regulation D offering from Las Vegas
Palimpsest Bio Corp., a Delaware biotech company incorporated in 2026, is raising up to $1M under Regulation D 506(b) with $172K committed so far from four investors. The company is based in Las Vegas and seeking a minimum investment of $10K per investor.
Note: Company incorporated in 2026 and filed first Form D in October 2026; very early-stage issuer with minimal capital raised to date.
How this compares
- Among 172 fund launches filed from NV in the same window it is larger than 41%; the NV median is $4.5M.
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
People on the filing
| Matthew Davin Korpela | Executive Officer, Director |
[email protected] · observed Work emails for the people on the filing, where the firm publishes or patterns them, labelled by confidence — subscribers
Signed by Matthew Korpela, Chief Executive Officer.
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.